Effect of imatinib mesylate (IM) on endothelial cells (EC) functions

被引：1
|
作者：
Venalis, P. [1 ,2 ,3 ]
Distler, O. [4 ,5 ]
Akhmetshina, A. [1 ,2 ]
Dees, C. [1 ,2 ]
Buch, N. [1 ,2 ]
Gay, S. [4 ,5 ]
Schett, G. [1 ,2 ]
Distler, J. H. W. [1 ,2 ]
机构：
[1] Univ Erlangen Nurnberg, Dept Internal Med 3, D-8520 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Inst Clin Immunol, D-8520 Erlangen, Germany
[3] Vilnius Univ, Fac Med, Ctr Rheumatol, Vilnius, Lithuania
[4] Univ Zurich Hosp, Ctr Expt Rheumatol, CH-8091 Zurich, Switzerland
[5] Univ Zurich Hosp, Zurich Ctr Integrat Human Physiol, CH-8091 Zurich, Switzerland
来源：
JOINT BONE SPINE | 2008年 / 75卷 / 02期
关键词：
D O I：
10.1016/j.jbspin.2008.01.018
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB16
引用
收藏
页码：248 / 248
页数：1
相关论文
共 50 条
  • [31] NESH protein expression switches to the adverse effect of imatinib mesylate
    Matsuda, Satoru
    Ichigotani, Yasukatu
    Okumura, Naoko
    Yoshida, Hitomi
    Kajiya, Yuka
    Kitagishi, Yasuko
    Shirafuji, Naoki
    MOLECULAR ONCOLOGY, 2008, 2 (01) : 16 - 19
  • [32] Imatinib mesylate has an inhibitory effect on hematopoiesis in a mice model
    Ye, Jie Yu
    Li, Su Yi
    Liang, En Yu
    Meng, Fan Yi
    Chong, Beng
    Yang, Mo
    BLOOD, 2013, 122 (21)
  • [33] Effect of St John's wort on imatinib mesylate pharmacokinetics
    Frye, RF
    Fitzgerald, SM
    Lagattuta, TF
    Hruska, MW
    Egorin, MJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (04) : 323 - 329
  • [34] Imatinib mesylate (IM) therapy in elderly patients affected by advanced gastrointestinal stromal tumor (GIST)
    D'Ambrosio, L.
    Ponzetti, A.
    Lista, P.
    Bombaci, S.
    Palesandro, E.
    Galizia, D.
    Aliberti, S.
    Allione, P.
    Manca, A.
    Gallo, S.
    Grignani, G.
    Aglietta, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Does imatinib mesylate (IM) affect longterm outcome in patients with gastrointestinal stromal tumors (GISTs)?
    Jin, Judy
    Robinson, Ann
    Willis, Joseph
    Hardacre, Jeffrey
    Kim, Julian
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2007, 205 (03) : S14 - S14
  • [36] Hypolipemiant besides antileukemic effect of imatinib mesylate (case report).
    Gologan, Radu Bucur
    Constantinescu, Gabriela
    Georgescu, Daniela
    Ostroveanu, Daniela
    Vasilache, Didona
    Dobrea, Camelia
    Iancu, Daniela
    Popov, Viola
    BLOOD, 2006, 108 (11) : 293B - 293B
  • [37] A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis.
    Chugh, R.
    Maki, R. G.
    Thomas, D. G.
    Reinke, D.
    Wathen, J. K.
    Patel, S.
    Priebat, D. A.
    Meyers, P. A.
    Benjamin, R. S.
    Baker, L. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 523S - 523S
  • [38] Evaluation of nilotinib (N) in advanced GIST previously treated with imatinib mesylate (IM) and sunitinib (S).
    Cauchi, C.
    Somaiah, N.
    Engstrom, P. F.
    Litwin, S.
    Lopez, M.
    Lee, J.
    Davey, M.
    Bove, B.
    Godwin, A. K.
    von Mehren, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Interobserver variability of size and density measurements on CT in patients with metastatic GISTS on imatinib mesylate (IM)
    Bulusu, V. R.
    Fawcett, S.
    Moyle, P.
    Carroll, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] A phase II study of imatinib mesylate (IM) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
    Lin, AY
    Fisher, G
    So, S
    Tang, C
    Levitt, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 363S - 363S
12345